Board Change • May 20
Less than half of directors are independent Following the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 4 non-independent directors. Independent Non-Executive Chairman Neil Warburton was the last independent director to join the board, commencing their role in 2021. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. Tillkännagivande • May 05
Belararox Limited has filed a Follow-on Equity Offering in the amount of AUD 4 million. Belararox Limited has filed a Follow-on Equity Offering in the amount of AUD 4 million.
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 33,333,333
Price\Range: AUD 0.06
Discount Per Security: AUD 0.003
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 33,333,334
Price\Range: AUD 0.06
Transaction Features: Subsequent Direct Listing Board Change • May 01
Less than half of directors are independent Following the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 4 non-independent directors. Independent Non-Executive Chairman Neil Warburton was the last independent director to join the board, commencing their role in 2021. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. Board Change • Dec 24
Less than half of directors are independent Following the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 3 non-independent directors. Independent Non-Executive Chairman Neil Warburton was the last independent director to join the board, commencing their role in 2021. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. Tillkännagivande • Sep 18
Belararox Limited, Annual General Meeting, Nov 11, 2025 Belararox Limited, Annual General Meeting, Nov 11, 2025. Tillkännagivande • Sep 15
Belararox Limited has filed a Follow-on Equity Offering in the amount of AUD 8.5 million. Belararox Limited has filed a Follow-on Equity Offering in the amount of AUD 8.5 million.
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 36,000,000
Price\Range: AUD 0.09
Discount Per Security: AUD 0.0054
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 58,444,444
Price\Range: AUD 0.09
Discount Per Security: AUD 0.0054
Transaction Features: Subsequent Direct Listing Board Change • Aug 18
Less than half of directors are independent Following the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 3 non-independent directors. Independent Non-Executive Chairman Neil Warburton was the last independent director to join the board, commencing their role in 2021. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. Board Change • Feb 04
Less than half of directors are independent Following the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 3 non-independent directors. Independent Non-Executive Chairman Neil Warburton was the last independent director to join the board, commencing their role in 2021. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. Tillkännagivande • Oct 31
Belararox Limited, Annual General Meeting, Nov 29, 2024 Belararox Limited, Annual General Meeting, Nov 29, 2024. Location: at suite 1, level 14, 221 st georges terrace, perth wa 6000 Australia Tillkännagivande • Oct 23
Belararox Limited has completed a Follow-on Equity Offering in the amount of AUD 8 million. Belararox Limited has completed a Follow-on Equity Offering in the amount of AUD 8 million.
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 27,400,000
Price\Range: AUD 0.25
Discount Per Security: AUD 0.015
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 4,600,000
Price\Range: AUD 0.25
Discount Per Security: AUD 0.015
Transaction Features: Subsequent Direct Listing Tillkännagivande • Sep 12
Belararox Limited (ASX:BRX) entered into binding agreement to acquire KCB Resources Pty Ltd for AUD 2.11 million. Belararox Limited (ASX:BRX) entered into binding agreement to acquire KCB Resources Pty Ltd for AUD 2.11 million on September 12, 2024. As part of acquisition Belararox limited will issue 9 million shares as follows 3 million Shares issued on execution of the Agreement, 1.5 million of which will be issued immediately without restriction with the Sellers undertaking to ensure that KCB Resources is debt-free at Settlement via a discharge and settlement of shareholder loans in exchange for Shares. The remaining 1.5 million Shares are subject to 12 months escrow 3 million Shares to be escrowed for 12 months and issued on the first anniversary of the date of execution of the Agreement and Subject to BRX’s right to elect to withdraw from the transaction prior to the second anniversary of the date of execution of the Agreement, a further 3 million Shares will be issued and escrowed for 12 months from the date of issue. New Risk • Mar 18
New major risk - Shareholder dilution The company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 57% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (25% average weekly change). Shareholders have been substantially diluted in the past year (57% increase in shares outstanding). Revenue is less than US$1m (AU$16k revenue, or US$10k). Minor Risk Market cap is less than US$100m (AU$21.7m market cap, or US$14.3m). Tillkännagivande • Mar 09
Belararox Limited has filed a Follow-on Equity Offering in the amount of AUD 4.000601 million. Belararox Limited has filed a Follow-on Equity Offering in the amount of AUD 4.000601 million.
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 14,287,860
Price\Range: AUD 0.28
Discount Per Security: AUD 0.0168
Security Features: Attached Options
Transaction Features: Subsequent Direct Listing New Risk • Jan 22
New major risk - Market cap size The company's market capitalization is less than US$10m. Market cap: AU$14.9m (US$9.82m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-AU$5.8m free cash flow). Shares are highly illiquid. Revenue is less than US$1m. Market cap is less than US$10m (AU$14.9m market cap, or US$9.82m). Minor Risk Shareholders have been diluted in the past year (30% increase in shares outstanding). Tillkännagivande • Jan 08
Belararox Limited Appoints Steve Garwin as Chief Technical Advisor Belararox Limited announced the appointment of Dr. Steve Garwin as Chief Technical Advisor for its recently acquired and prospective TMT Project in Argentina (TMT Project). Dr. Steve Garwin is a highly experienced exploration geologist with more than 35 years of experience with large- and small-scale mining companies. He is currently Chief Technical Adviser to SolGold Plc and Hot Chili Ltd, Senior Technical Advisor to Aurania Resources Ltd. and Technical Advisor to Japan Gold Corp. Dr. Garwin is a leading authority on porphyry, epithermal and Carlin - style mineralisation in the circum - Pacific Region and is well placed to advise and direct the Company's exploration strategies at the TMT Project. Dr. Garwin's experience, expertise and qualifications. Under his services contract with the Company, which is for an initial two-year period commencing January 2024, Dr. Garwin will provide guidance for the Company's exploration strategy at the TMT Project tenements. His role shall include site visits and the technical overview and direction of the Company's exploration programme, which is designed to develop a geological model and a resource /reserve estimate for the Project. Tillkännagivande • Nov 04
Belararox Limited (ASX:BRX) signed a non-binding terms of sheet to acquire the Solwezi East and Chantente exploration licences located in the Zambian Copperbelt from Chemopharm Limited. Belararox Limited (ASX:BRX) signed a non-binding terms of sheet to acquire the Solwezi East and Chantente exploration licences located in the Zambian Copperbelt from Chemopharm Limited on November 2, 2023. The acquisition includes two tenements (exploration licences) namely 19806-HQ-LEL (Solwezi East) and 19712- HQ-LEL (Chantente). In consideration of the Acquisition, on completion, the Company will: (d) pay to Chemopharm $100,000 in cash; (e) issue to Chemopharm or its nominee: (i) 750,000 fully paid ordinary shares in the capital of the Company (subject to a 12-month period of voluntary escrow from the date of issue of the shares); (ii) 1,000,000 unlisted options in the Company with an exercise price of $0.95 and expiring on 1 June 2024 (subject to cancellation if the term of both tenements are not extended or renewed for at least a period of two years or mining leases are not granted in respect of both tenements); (iii) 2,000,000 listed options in the Company (ASX: BRXOA) with an exercise price of $0.66 and expiring on 13 July 2026 (1,000,000 of which will be subject to voluntary escrow until the term of both tenements are extended or renewed for at least a period of two years or mining leases are granted in respect of both tenements); (iv) the following performance rights (convertible into quoted shares in the Company, expiring on 1 November 2027): (A) 500,000 performance rights with the following vesting milestone: the extension or renewal of both tenements for at least a period of two years or the grant of mining leases in respect of both tenements; (B) 1,000,000 performance rights with the following vesting milestone: on the acquisition of a further mining tenement by the Company in Zambia on terms satisfactory to the Company in all respects; (C) 2,000,000 performance rights with the following vesting milestone: three drilling intersection of at least 30 metres at 0.5% copper metal or a polymetallic equivalent on a tenement; (D) 1,000,000 performance rights with the following vesting milestone: upon a JORC compliant inferred resource being delineated on a tenement of greater than 250,000 t of contained copper metal or a polymetallic equivalent; and (E) 2,000,000 performance rights with the following vesting milestone: upon a JORC compliant inferred resource being delineated on a tenement of greater than 500,000 t of contained copper metal or a polymetallic equivalent. Subject to the execution of a definitive legally binding agreement between the parties, the Company anticipates that an extraordinary general meeting of the Company will be convened in January 2024 seeking shareholder approval for the issue of these securities. The acquisition of the tenements (Acquisition) is subject to the execution of a definitive legally binding agreement between the parties and other customary conditions precedent including: (a) the Company securing all shareholder and regulatory approvals both in Australia and Zambia required to complete the Acquisition including shareholder approval for the issue of the consideration securities referred to below; (b) completion of technical and legal due diligence by the Company in relation to the tenements satisfactory to the Company in its absolute discretion; and (c) the tenements being in good standing and full force and effect and free from any encumbrances or any liability to forfeiture or non-renewal under the relevant Zambian legislation and revelatory framework. Board Change • Nov 01
Less than half of directors are independent There are 5 new directors who have joined the board in the last 3 years. Of these new board members, 1 was an independent director. The company's board is composed of: 5 new directors. No experienced directors. No highly experienced directors. 1 independent director (4 non-independent directors). MD & Director Arvind Misra is the most experienced director on the board, commencing their role in 2021. Independent Non-Executive Chairman Neil Warburton was the last independent director to join the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity. Lack of experienced directors. Tillkännagivande • Oct 06
Belararox Limited, Annual General Meeting, Nov 27, 2023 Belararox Limited, Annual General Meeting, Nov 27, 2023. Agenda: To consider re-election of Directors. New Risk • Jun 27
New major risk - Market cap size The company's market capitalization is less than US$10m. Market cap: AU$14.8m (US$9.88m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-AU$5.5m free cash flow). Share price has been highly volatile over the past 3 months (17% average weekly change). Revenue is less than US$1m. Market cap is less than US$10m (AU$14.8m market cap, or US$9.88m). Minor Risks Less than 3 years of financial data is available. Shareholders have been diluted in the past year (21% increase in shares outstanding). Tillkännagivande • May 30
Belararox Limited Announces Board Changes Belararox Limited announced the following changes to the Board of Directors. The appointment of Jason Ward as a non executive director with effect from 1 June 2023; and the resignation of Michelle Stokes with effect from 1 July 2023. Mr. Ward, who is based in Mendoza, Argentina, holds a Bachelor of Applied Science, Geology and is a Fellow and Chartered Professional of the Australian Institute of Mining and Metallurgy. Mr. Ward is a director and shareholder of Condor Prospecting Pty Ltd, the company that will be responsible for the management and execution of the exploration activities at the TMT Project in Argentina. Mr. Ward has had a highly successful global career as an exploration geologist, having been involved in several discoveries in Oman, Laos, Papua New Guinea and Ecuador. He has over 25 years' experience working around the world, most recently in Ecuador where he was instrumental in the discovery of several copper gold deposits, including the Tier -1 Cascabel copper gold porphyry deposit for Solgold plc. In addition, Mr. Ward has an extensive track record of successfully working with local communities and safely managing exploration teams, working with people from diverse cultures in challenging social and physical terrain. Ms Stokes (BSc) who is a founder shareholder of the Company and has been a non- executive director since the Company was listed in January 2022, will retire as a director on 1 July 2023. Tillkännagivande • Feb 08
Belararox Limited Identifies Lithium Pegmatite Prospectivity At its Bullabulling Project Belararox Ltd. announced the identification of potential LCT mineralisation in its Bullabulling tenements, which were already considered highly prospective for gold. Belararox Limited's 100%-owned Bullabulling Project comprises 26 tenements over 50km2 to the west of Coolgardie in Eastern Goldfield of Western Australia, was initially considered prospective for gold deposits. The recent identification of pegmatites in the Bullabulling Project has underpinned a decision by Belararox to broaden its exploration activities at this prospect. The Company is now also assessing the potential of Lithium- Caesium-Tantalum (LCT) pegmatites across these tenements. The regional location of the Project in relation to peer Lithium Mineral Resources. The current global focus on battery metals, has targeted attention on the greenstone belts of the Yilgarn Craton as fertile corridors for LCT pegmatites. Several pegmatites have been mapped by the GSWA within, and in proximity, to the Bullabulling Project. The Bullabulling Project area comprises a sequence of ultramafics and mafic rock, which have been folded and thrust repeatedly. The mafics are the main host for gold mineralisation, including at the nearby Bullabulling and Gecko gold mines. Both 3D and 2D mineral potential modelling has identified several high priority targets related to west dipping contact between ultramafic and mafic units. These targets are still a priority for the Company. The Bali Monzogranite, in the east of the tenements, is a highly fractionated granite body associated with pervasive post-gold pegmatites and quartz veining. Both Ubini and Red Panda are located some 2km north of the main grouping of Bullabulling's eastern tenements in a similar geological setting with quartz and pegmatite veins in mafic rocks and both are considered an analogue for potential LCT mineralisation within the Bullabulling Project. Initial reconnaissance mapping on the Bullabulling Project has confirmed extensive quartz and pegmatite veins/sheets in the amphibolite units adjacent to the Bali Monzogranite in similar settings to the Red Panda and Ubini LCT pegmatites. Field mapping and Portable X-Ray Fluorescence ("XRF") surveying was conducted over the contact with Bali Monzogranite targeting both mafic rocks, fractionated granite, and quartz/pegmatite veins/float with rock chip samples collected at selected sites. Assay results from samples of quartz and pegmatite will be assessed in conjunction with XRF data collected during the reconnaissance work. Given the significant amount of vein material identified in both outcrop and as float, the Company considers that further appraisal of the potential for LCT pegmatites is warranted. Figure 5 highlights some of the higher priority target quartz veins and pegmatites identified during reconnaissance mapping. The main target area for pegmatite material comprises a corridor at the contact between the Bali Monzogranite in the east and the amphibolite rocks to the west, within the main eastern package of tenements of the Bullabulling Project. The western tenements will also be assessed for potential pegmatite occurrences. Tillkännagivande • Jan 31
Belararox Limited Announces the Imminent Commencement of A Phase 2 Drill Program At Its Belara/Native Bee Project (The Project) in NSW Belararox Ltd. announced the imminent commencement of a Phase 2 drill program at its Belara/Native Bee Project (the Project) in NSW. This drilling campaign aims to determine if the Project hosts additional significant zinc and copper mineralisation with the potential to build upon the known JORC mineral resources at Belara and Native Bee . The Belara Project comprises three contiguous 100% owned exploration licenses (one granted EL9184, two subject of applications ELA6176 and ELA6287) in central New South Wales (NSW). See Figure 1 for general location plan of the Belara project. The Belara project area is located at the northern end of the Hill End Trough in the eastern Lachlan Orogen in central NSW. The geology of the project area is dominated by volcanic and quartzose sandstone of the Chesleigh Group. It contains the Belara and Native Bee prospects, see Figure 2 for location of tenements and regional geology. Belararox' Phase 2 drill program, comprising of up to approximately 3,600m of diamond drilling at Belara and Native Bee, is scheduled to commence mid-February 2023. Phase 2 drilling by Ophir Drilling will focus on identifying additional mineralisation to the previously announced maiden Mineral Resource Estimate (MRE) at Belara and Native Bee, comprising an Inferred Resources of 5.0 million tonnes (Mt) at 3.41% Zinc equivalent (ZnEq) (see ASX announcement dated 3 November 2022). Significant exploration potential remains along strike and at depth of known sulphide resources. At Native Bee, Phase 2 drilling will aim to identify additional mineralisation along strike and in the vicinity of the old Native Bee mine area and assess further mineralisation potential identified in a coincident Gradient Array Induced Polarisation (GAIP) airborne magnetics first derivative (1VD) gravity anomaly, which extends from the area of the known mineral resource southwards over some 1,500m (Figures 3, 4 and 5; refer to ASX announcement dated 3 November 2022). At Belara, mineralisation is open to the north and down-dip, with the aim of identifying additional high-grade mineralisation during Phase 2 drilling. Drill hole BLRC019D from Phase 1 drilling intersected significantly wider and higher-grade base metal mineralisation than targeted (refer to ASX announcement dated 12 September 2022). Phase 2 drilling will target the continuation of high-grade mineralisation intersected in BLRC019D and from previous drilling (B021, B033 and B032; see Figure 6). Exploration Licence Applications (ELA6176 and ELA6287) are well advanced and are expected to be granted shortly. The granting of these applications will unlock a further 20km of prospective host rocks and structural corridor south of Belara and Native Bee where no exploration work has been carried out, a trend that includes the old Ben Buckley base metal deposit. In addition, a close spaced airborne magnetic survey will be completed over portions of the 20km structural corridor south of Belara and Native Bee, including ELA6176 once it is granted (Figure 7). It is envisaged that this survey will identify targets for follow-up ground truthing, including mapping, sampling, and ground-based geophysics. Board Change • Jan 10
Less than half of directors are independent Following the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 4 non-independent directors. Independent Non-Executive Chairman Neil Warburton was the last independent director to join the board, commencing their role in 2021. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. Tillkännagivande • Jan 03
Belararox Limited (ASX:BRX) has signed a Non Binding Terms Sheet all of the issued shares in Fomo Ventures No 1 Pty Ltd from Octo Opportunities Pty Ltd and BL Family Nominees Pty Ltd for AUD1 million. Belararox Limited (ASX:BRX) has signed a Non Binding Terms Sheet all of the issued shares in Fomo Ventures No 1 Pty Ltd from Octo Opportunities Pty Ltd and BL Family Nominees Pty Ltd for AUD1 million on January 3, 2023. BRX to pay a deposit of AUD 0.14 million to the Vendors as follows: A non- refundable deposit of AUD 0.36 million within seven (7) days of the Execution Date of the Terms Sheet (Exclusivity Fee); and AUD 0.11 million within seven (7) days of the execution of the Share Purchase Agreement. In consideration for the Acquisition, BRX will at settlement issue to the Vendors - 2,500,000 fully paid ordinary shares in the capital of BRX (Consideration Shares), subject to a 12-month voluntary escrow period applicable from the date of issue of the Consideration Shares; 1,000,000 options with an exercise price of AUD 0.95 and expiring on 6 June 2024 (Consideration Options), 10,500,000 Performance Shares (Performance Shares) as follows: 2,500,000 Stage 1 Performance Shares upon achieving a drilling intersection of at least 30m @ 1.0% ZnEq.; 4,000,000 Stage 2 Performance Shares upon achieving a JORC compliant Inferred Resource of at least 25Mt > 1% ZnEq @0.80% ZnEq Cut off. 4,000,000 Stage 3 Performance Shares upon achieving a JORC compliant Inferred Resource of at least 50Mt > 0.5% CuAuEq @0.30% CuAuEq Cut off. The Terms Sheet is subject to several conditions’ precedent including – If required, securing shareholder and regulatory approvals including ASX approval of the terms of the Performance Shares to be issued to the Vendors; Completion of technical, financial, corporate and legal due diligence to the satisfaction of BRX, including confirmation of the transfer of title to the Tenements and good standing of the Tenements; Completion of a site visit by the BRX technical team; Execution of suitable management agreements with the management team of the Vendors to enable management of the exploration of the Tenements and to provide marketing support to BRX; Negotiation and execution of a binding agreement reflecting the terms of the NBTS together with the Royalty Agreement; and Variations to certain payment provisions under the Option Agreements. The end date for the Acquisition is on February 28, 2023, or such other date as agreed in writing between the Parties. Board Change • Nov 16
Less than half of directors are independent Following the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 4 non-independent directors. Independent Non-Executive Chairman Neil Warburton was the last independent director to join the board, commencing their role in 2021. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. Recent Insider Transactions • Jun 17
Non-Executive Chairman recently bought AU$52k worth of stock On the 10th of June, Neil Warburton bought around 110k shares on-market at roughly AU$0.47 per share. This was the largest purchase by an insider in the last 3 months. This was Neil's only on-market trade for the last 12 months. Board Change • Apr 27
Less than half of directors are independent Following the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 3 non-independent directors. was the last director to join the board, commencing their role in . The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. Board Change • Feb 01
Less than half of directors are independent Following the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 3 non-independent directors. was the last director to join the board, commencing their role in . The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.